RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: A prospective study

International Journal of Molecular Sciences

Volumn 14, Issue 6, 2013, Pages 10683-10693

  Mercatali, Laura ^a   Ricci, Marianna ^a   Scarpi, Emanuela ^a   Serra, Patrizia ^a   Fabbri, Francesca ^a   Ricci, Rossana ^a   Liverani, Chiara ^a   Zanoni, Michele ^a   Zoli, Wainer ^a   Maltoni, Roberta ^a   Gunelli, Erica ^a   Amadori, Dino ^a   Ibrahim, Toni ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Bone metastases; NTX; OPG; RANK; RANK L

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANTINEOPLASTIC AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; IMIDAZOLE DERIVATIVE; PEPTIDE; TNFRSF11A PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG CANCER; MALE; OSTEOCLAST ACTIVITY; PATIENT MONITORING; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BLOOD; BONE NEOPLASMS; BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PEPTIDES; PROSPECTIVE STUDIES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84878169309     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140610683     Document Type: Article

References (28)

1. Mundy, G.R. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2, 584-593.
2. Ibrahim, T.; Barbanti, F.; Giorgio-Marrano, G.; Mercatali, L.; Ronconi, S.; Vicini, C.; Amadori, D. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: A retrospective study. Oncologist 2008, 3, 330-336.
3. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M.J. Cancer statistics 2007. CA Cancer J. Clin. 2007, 57, 43-66.
4. Coleman, R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer. Res. 2006, 12, 6243s-6249s.
5. Amadori, A.; Cascinu, S.; Conte, P.; Ibrahim, T. Osteoncology Textbook; Poletto Editore: Milan, Italy, 2010.
6. Lipton, A. Zoledronic acid: Multiplicity of use across the cancer continuum. Expert Rev. Anticancer Ther. 2011, 7, 999-1012.
7. Lipton, A.; Theriault, R.L.; Hortobagyi, G.N.; Simeone, J.; Knight R.D.; Mellars, K.; Reitsma, D.J.; Heffernan, M.; Seaman, J. Pamidronate prevents skeletal complications and its effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow up of two randomized, placebo-controlled trials. Cancer 2000, 88, 1082-1090.
8. Saad, F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin. Prostate Cancer 2005, 4, 31-37.
9. Rosen, L.S.; Gordon, D.; Tchekmedyian, S.; Yanagihara, R., Hirsh, V.; Krzakowski, M.; Pawlicki, M.; de Souza, P.; Zheng, M.; Urbanowitz, G.; et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-The zoledronic acid lung cancer and other solid tumors study group. J. Clin. Oncol. 2003, 21, 3150-3157.
10. Coleman, R.; Brown, J.; Terpos, E.; Lipton, A.; Smith, M.R.; Cook, R.; Major, P. Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. Cancer Treat. Rev. 2008, 34, 629-639.
11. Coleman, R.E. The role of bone markers in metastatic bone disease. Cancer Treat. Rev. 2006, 32, S1-S2.
12. Garnero, P.; Buchs, N.; Zekri, J.; Rizzoli, R.; Coleman, R.E.; Delmas, P.D. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer 2000, 82, 858-864.
13. Ulrich, U.; Rhiem, K.; Schmolling, J.; Flaskamp, C.; Paffenholz, I.; Sälzer, H.; Bauknecht, T.; Schlebusch, H. Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch. Gynecol. Obstet. 2001, 264, 186-190.
14. Jung, K.; Lein, M.; Stephan, C.; von hösslin, K.; Semjonow, A.; Sinha, P.; Loening, S.A.; Schnorr, D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int. J. Cancer 2004, 111, 783-791.
15. Kamiya, N.; Suzuki, H.; Yano, M.; Endo, T.; Takano, M.; Komaru, A.; Kawamura, K.; Sekita, N.; Imamoto, T.; Ichikawa, T. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Urology 2010, 75, 1446-1451.
16. Hatoum, H.T.; Lin, S.J.; Smith, M.R.; Barghout, V.; Lipton, A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: Analysis of a national medical claims database. Cancer 2008, 113, 1438-1445.
17. Hofbauer, L.C.; Neubauer, A.; Heufelder, A.E. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: Potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001, 92, 460-470.
18. Blair, J.M.; Zhou, H.; Seibel, M.J.; Dunstan, C.R. Mechanisms of disease: Roles of OPG, RANK-L and RANK in the pathophysiology of skeletal metastasis. Nat. Clin. Pract. Oncol. 2006, 3, 41-49.
19. Nicolini, A.; Tartarelli, G.; Carpi, A.; Metelli, M.R.; Ferrari, P.; Anselmi, L.; Conte, M.; Berti, P.; Miccoli, P. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs. MCA and MCA-CA15.3 vs. CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 2006, 6, 269.
20. Mountzios, G.; Dimopoulos, M.A.; Bamias, A.; Papadopoulos, G.; Kastritis, E.; Syrigos, K.; Pavlakis, G.; Terpos, E. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANK-L)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta. Oncol. 2007, 46, 221-229.
21. Mountzios, G.; Terpos, E.; Syrigos, K.; Papadimitriou, C.; Papadopoulos, G.; Bamias, A.; Mavrikakis, M.; Dimopoulos, M.A. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. Transl. Res. 2010, 155, 247-255.
22. Zhao, X.; Xu, X.; Guo, L.; Ragaz, J.; Guo, H.; Wu, J.; Shao, Z.; Zhu, J.; Guo, X.; Chen, J.; et al. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Res. Treat. 2010, 124, 733-743.
23. Lipton, A.; Cook, R.J.; Major, P.; Smith, M.R.; Coleman, R.E. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007, 12, 1035-1043.
24. Coleman, R.E.; Major, P.; Lipton, A.; Brown, J.E.; Lee, K.A.; Smith, M.; Saad, F.; Zheng, M.; Hei, Y.J.; Seaman, J.; et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 2005, 23, 4925-4935.
25. Ibrahim, T.; Sacanna, E.; Gaudio, M.; Mercatali, L.; Scarpi, E.; Zoli, W.; Serra, P.; Ricci, R.; Serra, L.; Kang, Y.; Amadori, D. Role of RANK, RANK-L, OPG and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. Clin. Breast Cancer 2011, 11, 369-375.
26. Sacanna, E.; Ibrahim, T.; Gaudio, M.; Mercatali, L.; Scarpi, E.; Zoli, W.; Serra, P.; Bravaccini, S.; Ricci, R.; Serra, L.; et al. The role of CXCR4 in the prediction of bone metastases from breast cancer: A pilot study. Oncology 2011, 80, 225-231.
27. Terpos, E.; Szydlo, R.; Apperley, J.F.; Hatjiharissi, E.; Politou, M.; Meletis, J.; Viniou, N.; Yataganas, X.; Goldman, J.M.; Rahemtulla, A. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index. Blood 2003, 102, 1064-1069.
28. Mercatali, L.; Ibrahim, T.; Sacanna, E.; Flamini, E.; Scarpi, E.; Calistri, D.; Ricci, M.; Serra, P.; Ricci, R.; Zoli, W.; et al. Bone metastases detection by circulating biomarkers: OPG and RANK-L. Int. J. Oncol. 2011, 39, 255-261.